A new study by Monash University medicine safety experts found the use of gabapentinoids—medicines widely used to treat ...

A new study by medicine safety experts found the use of gabapentinoids -- medicines widely used to treat neuropathic pain -- increased the risk of hip fractures, especially in older patients who were ...

An innovative New South Wales government funded statewide Cannabis Medicines Advisory Service (CMAS) operated between January 2018 and June 2022. The service provided comprehensive patient-specific ...

Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

The study, published today in JAMA Network Open, tracked patients hospitalized for hip fractures in Victoria, Australia from ...

The trial investigates the efficacy, safety and tolerability of QUTENZA ® (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) and if successful could support an extension of ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) stock is trading higher on Monday after the company released new preclinical ...

The FDA has placed a trial of Rapport Therapeutics’ epilepsy drug for a type of nerve pain on hold while the biotech tweaks ...

"This has been an exceptional year with countless acts of remarkable philanthropy in our valley," said AFP board president ...

Biotech companies have brought many important treatments to market, from ones that address rare diseases to ones that handle ...

The new preclinical data show that Ketamir-2 is 60% more effective than the FDA-approved neuropathic pain treatment gabapentin in reducing chemotherapy-induced pain. The study used the paclitaxel ...